Updated EULAR recommendations on the use of DMARDs for peopl

Updated EULAR recommendations on the use of DMARDs for people with RA

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the field, and their updates are relied upon by many healthcare professionals, professional organizations and other stakeholders to offer an up-to-date and robust analysis on an optimal approach to the application of available treatment options in clinical practice.

Related Keywords

United States , Copenhagen , Køavn , Denmark , Emily Henderson , Pharmacovigilance Risk Assessment Committee , Lab Diagnostics Automation , Drug Administration , European Medicine Agency , American College Of Rheumatology , Lab Diagnostics Automation Industry , United States Food , American College , Rheumatic Diseases , Automation Industry Focus , Clinical Trial , Drugs , Wood , Healthcare , Inase , Kinase Inhibitor , Necrosis , Heumatology ,

© 2025 Vimarsana